Drug Combination Details
| General Information of the Combination (ID: C85983) | |||||
|---|---|---|---|---|---|
| Name | Tretinoin NP Info | + | Paricalcitol Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Obstructive nephropathy
[ICD-11: GB56]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | The animal model was established by unilateral ureteral obstruction (UUO) in male CD-1 mice. | |||||
| Experimental
Result(s) |
Combination therapy of paricalcitol and trandolapril had additive efficacy in retarding renal scar formation during obstructive nephropathy. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009 Dec;76(12):1248-57. | |||
